Search Results for 'Biosimilars'

Contract Service Directory Companies

View All Buyers Guide Companies »

Contract Service Directory Categories

View All Categories »

• Biosimilars
  

  The U.S. Biosimilars Market: Shaking the “Laggard” Label

  Biosimilar uptake set to reshape the U.S. market

  Katya Svoboda and Bob Swann, ICON 05.05.20
  

  ---

• Bio News | Biosimilars
  

  Know the Challenges of Biosimilar Manufacturing

  Best Practices for a Competitive Market

  Jerry Martin, Pharmaceutical and Life Sciences Consultant to PMMI, and, Dr. Michiel Ultee, Principal, Ulteemit BioConsulting, LLC 04.11.18
  

  ---

• Biosimilars | Drug Development
  

  Differentiating in the Biosimilar Market: Surviving the Cost of Entry

  Companies need to improve customer experience, produce additional evidence, and create valuable engagement with stakeholders

  Michael Turner and Magnus Franzen, Life Sciences Experts, PA Consulting Group 03.01.18
  

  ---

• Biosimilars
  

  CMOs & Biosimilars Mfg. in the U.S.

  Biosimilars are moving from novel opportunity to mainstream product

  Eric S. Langer and Ronald A. Rader, BioPlan Associates 04.20.17
  

  ---

• APIs | Biosimilars | Process Development | Supply Chain

  Biosimilars Improving Efficiency, Cost for All Biologics

  Now that the FDA has just approved its first product under biosimilar regulations—Zarxio—containing filgrastim (G-CSF), a biosimilar version of Neupogen from Amgen, we can expect some more rapid shifts in the market. Factors like how this…

  Eric S. Langer and Ronald A. Rader, BioPlan Associates 04.01.15
  

  ---

• Biosimilars

  The Expanding World of Fast-Track Biosimilars

  As the FDA approves the first biosimilar in the U.S., questions remain

  Adele Graham-King, Contributing Editor 04.01.15
  

  ---

• Biosimilars

  Biosimilars and Biobetters: From Basic Similarity to Simplified Innovation

  Everyone talks about biosimilarity, but it’s clarifying the differences between biosimilars, biobetters and me-too products that will be critical to biological innovation and pricing

  Fereshteh Barei, Dauphine University 06.18.14
  

  ---

• Bioassay Development | Biologics, Proteins, Vaccines | Biosimilars | Chemistry | Drug Development | Methods Development | Process Development | Toxicology
  

  Studying Binding in BIosimilars

  Bio-Layer Interferometry can be a useful addition to the orthogonal analysis toolkit required for characterizing biosimilars

  Michael Sadick , Catalent 06.03.14
  

  ---

• Biologics, Proteins, Vaccines | Biosimilars | Cold Chain Management | Fill/Finish | Injectables | Logistics | Serialization
  

  Access to Biosimilars

  Patient access issues and opportunities

  Peyton R. Howell, AmerisourceBergen Consulting Services 05.04.12
  

  ---

• Biosimilars | Clinical Trials | Logistics | R&D

  Biosimilars and Cold Chain Issues

  Good distribution practices will impact follow-on biologics

  Kevin O'Donnell 03.04.09
  

  ---